nVerses Capital’s Denali Therapeutics DNLI Stock Holding History

nVerses Capital’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-9,900	Closed	-$288K	–	253
2024 Q3	$288K	Buy	+9,900	New	+$245K	0.13%	249

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

nVerses Capital's DNLI Position: Q4 2024 in Review

nVerses Capital sold out of Denali Therapeutics (DNLI) in Q4 2024, closing a stake of 9,900 shares — an estimated $288K sold.

nVerses Capital first reported a position in DNLI in Q3 2024 and held it in 1 quarter. The position peaked at $288K in Q3 2024. 223 funds tracked by Wall St. Rank hold DNLI as of Q4 2024.

nVerses Capital reported no remaining Denali Therapeutics position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 9,900 Denali Therapeutics shares in Q4 2024, an estimated $288K.
nVerses Capital first reported a position in Denali Therapeutics in Q3 2024 and held it in 1 quarter.
nVerses Capital's Denali Therapeutics position peaked at $288K in Q3 2024.
223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.